Infectious disease Lassa fever Epidemiology Enzyme-linked immunosorbent assay (ELISA) Sierra Leone a b s t r a c t Lassa fever is a rodent-borne illness that is endemic to parts of sub-Saharan Africa, including Sierra Leone, Nigeria, and Guinea. The disease is named after the town of Lassa, Nigeria where it was discovered in 1969. This data article focuses on the epidemiology of Lassa fever in Sierra Leone following a decade-long civil war that ended in 2002. The data were collected at Kenema Government Hospital (KGH) in Kenema, Sierra Leone, which maintains the country's only Lassa fever treatment facility and a biosafety level 3 (BSL-3) laboratory. The key data set variables include Lassa fever serostatus determined using antigen (Ag), immunoglobulin M (IgM), and immunoglobulin G (IgG) ELISA diagnostic techniques; and patient demographics, survival outcome, and treatment (ribavirin) status. The individual data used to generate the graphs 
Value of the data
Data classify Lassa fever serostatus according to acute, recent, prior, and absence of prior exposure; Patient survival outcomes are included for calculating Lassa fever case fatality rates; Data cover Sierra Leone's post-conflict period and may be used as a benchmark for related Lassa fever research; and Individual data are provided to allow for linkage with other environmental or epidemiological data sets.
Data
The data here include clinical and laboratory outcomes captured through clinical questionnaires and human blood sample screening for Lassa virus disease at Kenema Government Hospital (KGH) in Kenema, Sierra Leone. Screening techniques included antigen (Ag), immunoglobulin M (IgM), and immunoglobulin G (IgG) ELISA. The data set contains 1740 observations collected between January 1, 2008 and December 31, 2012. Each observation corresponds to the date of first blood draw at KGH or one of its peripheral health units. The data are classified by 14 variables, including subject demographics, survival outcome, month and year of screening, Lassa fever serostatus, and treatment (ribavirin) status. The full data set includes observations for 190 acute Lassa fever exposures, 407 recent Lassa fever exposures, and 1143 observations with absence of recent Lassa exposure. Data are provided in Microsoft Excel format (version 2013; Redmond, WA). The primary limiting factor of the data is the self-reporting of the subjects who contributed blood samples.
Study site
Kenema Government Hospital (KGH) is situated in southeast Sierra Leone about 40 miles (64 km) from the Liberian border. KGH is one of 31 government hospitals in Sierra Leone and is coordinated with 788 functioning public health units (PHUs; [2] ). KGH maintains the only Lassa treatment facility and Lassa fever isolation ward in Sierra Leone (and one of the few Lassa fever isolation wards in the world) and is equipped with a biosafety level 3 (BSL-3) laboratory for screening suspected cases of Lassa fever. All data for this article were captured at KGH.
Experimental design, materials, and methods
The full data set includes 1740 observations based on the following criteria: The data set includes 1740 observations for subjects with Ag and IgM ELISA serostatus outcomes, including 476 observations for subjects admitted to the KGH Lassa Ward. Admission of suspected Lassa cases was determined according to the suspected case definition for Lassa fever detailed in Shaffer et al. [1] . Demographic data were usually unavailable for subjects dying prior to hospital admission. All data were captured on clinical presentation, save for patient survival outcome and treatment (ribavirin) status. An observation summary for the full data set is shown in Table 1 .
The primary outcome was Lassa fever serostatus classified into four categories as detailed by Branco et al. Table 1 Full data set observation summary (n ¼ 1740 observations). Immunoglobulin G (IgG) ELISA testing began at KGH in 2010 to for detecting prior, long-term Lassa exposure. The methodology of the ELISA procedures (adapted from [1] ) are detailed in the two subsections below [1, 4] .
Lassa fever recombinant antigen immunoassays at KGH
The immunoassays for these data were designed to detect Lassa virus (LASV) antigens or antibodies circulating in Sierra Leone or its surrounding countries. Confirmation studies of earlier works indicated that there are three diverse LASV lineages in Nigeria (lineages I, II, and III), but only a single lineage (IV) in Sierra Leone. Performance of the Recombinant Lassa (ReLASV) Diagnostics system versus detection of LASV viremia by reverse transcriptase polymerase chain (RT-PCR) was evaluated at KGH between 2012-2013 (unpublished data). Limits of detection and quantitation of the recombinant antigen-based Lassa fever ELISAs were applied based on the upper 95th percentile obtained with panels of sera from U.S. and Sierra Leonean donors without detectable LASV antigens or immunoglobulin M or G antibodies to LASV recombinant proteins. IgG depletion studies (protein A) demonstrated that the LASV IgM assay only detects anti-LASV IgM (not IgG) and conversely that the IgG assay has a high specificity for anti-LASV IgG. Upon initial presentation, screening with the ReLASV diagnostic assays was capable of identifying 95% of active LF cases as confirmed by RT-PCR performed at KGH, rising IgM titers or IgM to IgG seroconversion. The diagnostic assays failed to detect a low percentage ( o 5%) of resolving or less severe Lassa cases with low virus load that were generally associated with low mortality. Combining the nucleoprotein antigen detection (Ag-capture ELISA) with anti-LASV IgM reactivity (IgM-capture ELISA) yielded a 98% negative predictive value.
Accession number
Recombinant nucleoprotein, glycoprotein, and Z protein from lineage IV LASV Josiah strain (a Sierra Leone isolate; ADY11071) were used in the IgM and IgG-capture ELISAs [5] . These recombinant proteins were also used to immunize goats and mice for use in the ReLASV Ag-capture ELISA.
Serostatus break points
The serostatus break points were based on the optical density values for a set negative (for Lassa) control samples. Specifically, indeterminate and positive classifications were set at 1.5 and 2.5 standard deviations (respectively) above the average of the optical density values over a group of negative (for Lassa) control samples. The break points were calculated by calendar year to account for environmental changes and technological advancements. Indeterminate serostatus classifications were ultimately considered as absent of Lassa exposure (Ag-/IgM-) for the final data set.
Calculation of case fatality rates
Survival outcome was measured at hospital discharge or following patient consultation for subjects not admitted to KGH. Those survival outcomes for subjects transferred from the KGH Lassa Ward to other hospital units were considered as unknown. To illustrate the use of the survival outcome data included with this article, case fatality rates (CFRs) for Lassa fever over the data collection period are shown in Table 2 .
Conservatively estimating the CFRs among acute Lassa fever exposures by considering the missing outcome responses as hospital discharges yields a CFR of 57.3% (n ¼ 109/190). Omitting the unknown survival outcomes from the calculation yields a CFR of 69.0% (n ¼ 109/158). The survival outcome data included with this article likely underestimate patient mortality as subjects were occasionally transferred from the KGH Lassa Ward to other hospital units and their survival outcomes were considered as unknown. It was common for death to occur in patients discharged against medical advice, which were considered here as typical hospital discharges. Data following hospital discharge were usually unavailable and considered as unknown.
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